Minerva Neurosciences Management
Management criteria checks 4/4
Minerva Neurosciences' CEO is Remy Luthringer, appointed in Nov 2014, has a tenure of 11.25 years. total yearly compensation is $1.21M, comprised of 53.6% salary and 46.4% bonuses, including company stock and options. directly owns 0.43% of the company’s shares, worth $750.37K. The average tenure of the management team and the board of directors is 10.9 years and 10.5 years respectively.
Key information
Remy Luthringer
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 53.64% |
| CEO tenure | 11.3yrs |
| CEO ownership | 0.4% |
| Management average tenure | 10.9yrs |
| Board average tenure | 10.5yrs |
Recent management updates
Recent updates
Minerva says FDA declined to accept marketing application for schizophrenia drug
Oct 17Minerva Neurosciences: Biotech On The Move
Aug 29Minerva stock rises on filing for FDA approval of schizophrenia therapy
Aug 22We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely
Jun 22
Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?
Jan 26Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation
Oct 02Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares
Mar 03What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition
Jan 27We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate
Dec 23
A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns
Nov 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$14m |
| Jun 30 2025 | n/a | n/a | US$11m |
| Mar 31 2025 | n/a | n/a | US$6m |
| Dec 31 2024 | US$1m | US$649k | US$1m |
| Sep 30 2024 | n/a | n/a | -US$3m |
| Jun 30 2024 | n/a | n/a | -US$34m |
| Mar 31 2024 | n/a | n/a | -US$32m |
| Dec 31 2023 | US$2m | US$624k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$28m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$1m | US$600k | -US$32m |
| Sep 30 2022 | n/a | n/a | -US$47m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$51m |
| Dec 31 2021 | US$1m | US$585k | -US$50m |
| Sep 30 2021 | n/a | n/a | -US$36m |
| Jun 30 2021 | n/a | n/a | -US$35m |
| Mar 31 2021 | n/a | n/a | US$5m |
| Dec 31 2020 | US$2m | US$565k | US$2m |
| Sep 30 2020 | n/a | n/a | -US$21m |
| Jun 30 2020 | n/a | n/a | -US$27m |
| Mar 31 2020 | n/a | n/a | -US$69m |
| Dec 31 2019 | US$1m | US$543k | -US$72m |
Compensation vs Market: Remy's total compensation ($USD1.21M) is about average for companies of similar size in the US market ($USD1.44M).
Compensation vs Earnings: Remy's compensation has been consistent with company performance over the past year.
CEO
Remy Luthringer (64 yo)
Dr. Remy Luthringer, Ph D., serves as a Clinical Advisor to the Medicxi investment team and a Member of the Co-Founding team at Medicxi Ventures (UK) LLP. He has played an active role in several Index Vent...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 11.3yrs | US$1.21m | 0.43% $ 750.4k | |
| President | 4.3yrs | US$919.73k | 0.12% $ 208.4k | |
| Senior VP | 11.6yrs | US$754.16k | 0.040% $ 71.1k | |
| Senior VP & COO | 11.6yrs | US$1.49m | no data | |
| Vice President of Investor Relations & Corporate Communications | 10.5yrs | no data | no data | |
| Chief Medical Officer | 9.2yrs | US$657.47k | no data |
Experienced Management: NERV's management team is seasoned and experienced (10.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 11.3yrs | US$1.21m | 0.43% $ 750.4k | |
| Independent Director | 11.6yrs | US$67.50k | 0.0059% $ 10.3k | |
| Independent Director | 8.2yrs | US$75.63k | 0.0029% $ 5.1k | |
| Lead Independent Director | 10.3yrs | US$84.00k | 0.055% $ 97.2k | |
| Independent Director | 10.8yrs | US$70.13k | 0% $ 0 | |
| Director | less than a year | no data | no data |
Experienced Board: NERV's board of directors are seasoned and experienced ( 10.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/02 10:04 |
| End of Day Share Price | 2026/01/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Minerva Neurosciences, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jason Butler | Citizens JMP Securities, LLC |
| Douglas Tsao | H.C. Wainwright & Co. |